C-Trac for Carpal Tunnel Syndrome

ABSTRACT

The purpose of the study was to evaluate the efficacy of the CTRAC device by the company MeDevice and approved by the FDA, in patients diagnosed with Carpal Tunnel Syndrome (CTS), shown through electromyographic studies and with a minimum pain level of 5/10, on a scale of pain between 0 and 10 (“VAS”).

The sample consisted of eighteen (18) patients from the Aguadilla Region. They were treated using only CTRAC traction, three times (3) a day, for four weeks (4), without any conservative medicinal treatment, physical therapy, occupational therapy, splints, visits to the doctor or other medical treatments.

The results clinically and statistically showed a constant decrease in the symptoms of pain, numbness and tingling according to the numerical average of the “Visual Analog Scale (VAS)” measurements of the patients, in accordance with their level of severity, between Baseline and the fourth week of follow-up (Graphs I, II, III, IV, V, VI). In addition, the frequency with which patients woke up at night decreased (Table VIII).

Amongst the participating patients, 11 (61.11%) expressed a high level of satisfaction, while 5 (27.78%) expressed an average level and 2 (11.11%) expressed a low level of satisfaction with the CTRAC treatment (Table IX).

Clinical Finding: CTRAC traction is effective for treating symptoms of CTS.

C TRAC Home Page
Ordering C TRAC